At the news
? BULLISHIMPACT 8/10 DEFM14A filed Apr 1, 2026 at 16:53 ET
Penumbra Inc is being acquired by Boston Scientific in a mixed cash-and-stock deal valued at $374.00 per share, representing a 26% premium to Penumbra's unaffected stock price. The Penumbra board unanimously recommends approval, citing strategic benefits from Boston Scientific's global scale. Regulatory approvals are pending, including a Second Request from the FTC, with closing expected in 2026.
- Deal valued at $374.00 per Penumbra share, combining cash ($374.00) and stock (3.8721 Boston Scientific shares) options for shareholders
- 26.74% of shares will receive stock consideration, 73.26% will receive cash, subject to proration
- Perella Weinberg Partners issued a fairness opinion supporting the deal's financial terms
- Boston Scientific will pay a $900 million termination fee if antitrust approvals are denied
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access